Background: Despite active research in ovarian cancer immunotherapy, standard of care for ovarian
cancer remains surgery and (neo)adjuvant chemotherapy. Patients often develop secondary
resistance to chemotherapy, leading to recurrence. Since most mouse models have had
a poor translational efficiency so far, there is a need for new therapy development
strategies. We here present a mostly human-based pipeline that we have used for target
identification and drug development and testing.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
P01.04
Identification
Copyright
© 2018 Published by Elsevier Inc.
